Anti-Mouse TIGIT (1G9) – FITC

Recombinant murine TIGIT tetramers.

This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Blue Laser (488 nm)

Clone 1G9 activity is directed against mouse TIGIT.

TIGIT is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells¹. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin1-4, poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)². TIGIT is an attractive target for cancer therapy due to its role as an immune checkpoint^1,3. Immunotherapy targeting TIGIT and the PD-1/PD-L1 pathway is capable of tumor suppression.

1G9 was generated by immunizing TIGIT^-/- mice with recombinant mouse TIGIT tetramers³. Draining lymph nodes were collected and fused with Sp2/0-Ag14. Supernatants were screened for specific binding by anti-TIGIT ELISA and flow cytometry. Hybridomas that showed TIGIT-specific binding were expanded and subcloned and single colonies sorted by flow cytometry. Comparative immunofluorescence staining of activated primary TIGIT-expressing wildtype T cells and TIGIT^-/- T cells was performed to confirm specificity. 1G9 was found to fully block TIGIT binding to CD155, a high-affinity TIGIT ligand. However, 1G9 does not deplete TIGIT⁺ cells in vivo under steady-state conditions. Additionally, 1G9 does not affect T cell proliferation in vitro. 1G9 has agonistic anti-TIGIT activity in vivo, leading to a reduction in T cell expansion and pro-inflammatory cytokine production, and is also able to reduce experimental autoimmune encephalomyelitis (EAE) severity in mice.

TIGIT is expressed on NK cells, activated T cells, memory T cells, and a subset of regulatory T cells.

CD155 (PVR) and CD112 (PVRL2)

Q495A1

1 Harjunpää H, Guillerey C. Clin Exp Immunol. 200(2):108-119. 2020.
2 Boles KS, Vermi W, Facchetti F, et al. Eur J Immunol. 39(3):695-703. 2009.
3 Dixon KO, Schorer M, Nevin J, et al. J Immunol. 200(8):3000-3007. 2018.
4 Chen Y, Huang H, Li Y, et al. Front Immunol. 13:832230. 2022.
5 Zhou XM, Li WQ, Wu YH, et al. Front Immunol. 9:2821. 2018.
6 Wu L, Mao L, Liu JF, et al. Cancer Immunol Res. 7(10):1700-1713. 2019.
7 Peng H, Li L, Zuo C, et al. Front Immunol. 13:1039226. 2022.
8 Stirm K, Leary P, Wüst D, et al. J Immunother Cancer. 11(2):e006263. 2023.
9 Schorer M, Rakebrandt N, Lambert K, et al. Nat Commun. 11(1):1288. 2020.
10 Freed-Pastor WA, Lambert LJ, Ely ZA, et al. Cancer Cell. 39(10):1342-1360.e14. 2021.
11 Ozmadenci D, Shankara Narayanan JS, et al. Proc Natl Acad Sci U S A. 119(17):e2117065119. 2022.